|
|
This is only a preview of the paper
Click here to register and get the full text.
Existing members click here to login
|
|
|
Review of recent trends and developments 1st half, 2003
The Chinese pharmaceutical industry and market has been relatively quiet in the first and second quarter of 2003 without any major regulatory or policy changes. ... The growth of private medical institutions is gradually changing the horizon of medical and pharmaceutical businesses in China. Impacts are beginning to be felt in areas such as pharmaceutical marketing, sales and distribution.
Meanwhile, the government is making a greater effort to ensure traditional Chinese medicine (TCM) plays a more important role in improving the health of millions of Chinas rural people. ...
Chinas new Drug Registration Procedure (DRP), which came into effect on December 1, 2002, is beginning to reshape the Chinese pharmaceutical industry and market. ...
The new DRP changes the landscape of the local pharmaceutical companies which concentrate on copy drug products, and it is believed that the impacts are mostly positive for local companies and negative for some foreign companies. As a result of the new DRP, costs and time required for registering generic pharmaceutical products are sharply reduced under the abbreviated applications, while copy products that can be classified as new drugs will continue to receive exclusivity protection under ˇ°surveillance periodsˇ±. Foreign companies can expect more competition from local pharmaceutical companies. ...
A number of multinationals in Shanghai raised their disagreement, through Foreign Research-Based Pharmaceutical Industry Association in China, to the Shanghai government over a Shanghai government rule issued in December, 2002 governing hospital drug purchasing tendering in Shanghai.
Approximate Word count = 1123
Approximate Pages = 4.5
(250 words per page double spaced)
|
|
|
|
|
|